| Date | Title | Description |
| 11.08.2026 | HHT Patients Get First Phase 3 Drug Trial After 130 Years Without Treatment | By Donald C. Case
Published: Aug 11 2026, 10:53 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 12.02.2026 | J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research | SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a l... |
| 29.02.2024 | Often misdiagnosed, it's time to raise awareness of the rare disease amyloidosis | (BPT) - What started as a dream trip to Hawaii became a medical turning point for Sally Cox. While snorkeling in the crystal-clear waters, she suddenly found it difficult to breathe and nearly drowned. Shocked, scared and confused, she imme... |
| 04.10.2022 | A top Wall Street analyst names 3 tiny biotechs that look like takeout targets — including one that could jump more than 1,000% | The British pharma giant AstraZeneca has quietly been working on gene-editing research over the past few years. AstraZeneca This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Seve... |
| 08.04.2021 | FDA inspection of Emergent’s Baltimore site in 2020 raises new questions | The FDA on Thursday raised fresh quality concerns about Emergent BioSolutions’ manufacturing site in Baltimore, which has more recently been taken over by J&J after an error caused the site to discard about 15 millio... |
| 04.04.2021 | J&J Takes Over at Emergent Vaccine Plant With Aid From Biden
J&J Takes Over at Emergent Vaccine Plant With Aid From Biden | (Bloomberg) --
Johnson & Johnson, with help from the Biden administration, is taking over a Baltimore vaccine production facility that was the site of a major manufacturing error last month -- and moving production of material for a sec... |
| 04.04.2021 | Johnson & Johnson takes control of COVID vaccine output in Baltimore | Sign up for our daily briefingMake your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Enter your email address
Please enter a valid email.
Please enter a valid email.
Subscription failedSub... |
| 06.01.2021 | AstraZeneca's Farxiga gets rough FDA review date for groundbreaking move into chronic kidney disease | AstraZeneca’s Farxiga broke ground last year with an FDA nod for heart failure patients with or without type 2 diabetes — a first-in-class approval. But Farxiga isn’t done innovating and is now looking at a approval in the c... |
| 28.09.2016 | Hub appeal: AstraZeneca is marshaling 350-plus R&D troops in new South San Francisco campus | In biopharma, the big global hubs have become irresistible attractions as trophy locations suck in thousands of R&D jobs from the giants as well as startups. And AstraZeneca, which has been pushing an R&D makeover fo... |
| 18.05.2015 | AstraZeneca invests in new biologics manufacturing facility in Södertälje, Sweden | AstraZeneca invests in new biologics manufacturing facility in Södertälje, Sweden
18-05-2015
AstraZeneca today announced that it plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicine... |
| 22.03.2013 | Skepticism greets AstraZeneca in second round of changes announced this week | Fabian Wenner, an analyst with Kepler Capital Markets SA in Zurich was not impressed by the changes. In an interview with Bloomberg, he said: “I’m disappointed because Pascal didn’t see a need for a quick fix,” such as an acquisition. “They... |
| 18.03.2013 | AstraZeneca shakes up R&D division with 1,600 staff cuts and shift to biotech hot spots (video) | The pharmaceutical company said shifting its R&D sites to “bioscience hot spots” will make it easier to develop collaboration and partnership agreements. It will also help teams work more closely “to create a more vibrant environment” t... |
| 05.09.2012 | FDA faces curse of double-edged sword over downside of accelerated drug approvals | Although European regulators asked for label changes, but said the drug’s benefits are still worth the risk for appropriate patients, according to Fierce Pharma. The authors express concern that with the U.S. Senate’s push for an expansion ... |
| 05.07.2012 | Pitches unplugged: Startup developing iPad app to determine real reasons people don’t take their meds (video) | But the company’s primary interest is advancing ownership of a diabetes model for which it plans to partner with a payer and is looking to raise $1 million to develop what will be an iPad diagnostic tool to identify noncompliance with treat... |
| 13.04.2012 | AstraZeneca CEO faces familiar question on how to grow | Even Glass Lewis & Co., a proxy firm which seemed to support the management in its most recent report to AstraZeneca shareholders, acknowledged the patent cliff concerns:
The company faces one of the highest exposures to U.S. drug-paten... |
| 28.02.2012 | FDA’s new statin label warning about diabetes risk may have little effect | In evaluating the new warning U.S. regulators are issuing on statin prescription labels, many physicians are likely to take the view that high cholesterol poses a greater risk to their patients than potential side effects like diabetes, mem... |
| 19.01.2012 | FDA rejects diabetes drug from Bristol-Myers Squibb, AstraZeneca | The FDA had delayed making a decision about the drug last October following an FDA advisory regulatory committee recommendation to reject approval of dapagliflozin in July over safety concerns tied to bladder cancer in phase 2b and phase 3 ... |
| 18.12.2011 | 5 healthcare social media tips that break the mold for pharma, med tech | Healthcare social media is becoming a necessity for pharmaceutical and medical device companies. With so much word of mouth recommendations being fueled by Facebook, Twitter and YouTube, to name a few, many industries that have a consumer m... |
| 14.11.2011 | Endo Pharmaceuticals ends development of drug for growth hormone condition | Additionally, Endo discontinued development of the octreotide implant for the treatment of carcinoid syndrome because market research found it faced commercial challenges with physician acceptance and the expected rate of existing patients ... |
| 02.11.2011 | Endo Pharmaceuticals gets green light for generic version of Plendil | Endo, in Chadds Ford, Pennsylvania, saw a 439 percent surge in generic drug sales in the third quarter over the previous year to $148 million, primarily driven by its acquisition of Qualitest Pharmaceuticals in Huntsville, Alabama.
The comp... |
| 27.10.2011 | Biotech forum offers stage for new and mature entrepreneurs | “It’s such an exciting opportunity to bring scientists together to rub elbows with business people. We were very pleased with the new format,” Sheft said.
In the company showcase, about 20 startup companies pitched for investment. There was... |
| - | Stocks making the biggest moves midday: Tesla, Rivian, XPeng and more | Check out the companies making headlines in midday trading.
Electric vehicles — Electric vehicle makers such as Rivian Automotive surged following Tesla’s better-than-expected second-quarter production and delivery numbers. Rivian jumped 17... |
| - | Stocks making the biggest moves in the premarket: Tesla, Apple, AstraZeneca and more | Check out the companies making headlines in premarket trading.
Tesla — Tesla shares popped nearly 7% after the electric vehicle company posted second-quarter delivery and production numbers that topped Wall Street’s expectations. Deliveries... |
| - | FDA faces curse of double-edged sword over downside of accelerated drug approvals | The U.S. Food and Drug Administration frequently finds itself criticized for taking too long to approve drugs and devices, increasing the cost (and subsequent fundraising pressure) for drug developers and medical device makers to get their ... |
| - | Advancing our blueprint for the new era of cancer care | By Chatrick Paul, SVP, Head of US Oncology Business, AstraZeneca
While the global pandemic has disrupted cancer care services globally, clinical progress in the oncology field has certainly not slowed down. On the heels of the American Soci... |
| - | How a leading company in respiratory medicine is pushing the boundaries in immunology | Each year, innovation continues to push the boundaries of science, resulting in research that delivers life-changing medicines to those who need it most. One company is propelling insights and learnings forward in immunology by understandin... |
| - | Following the science to improve patient outcomes in respiratory & immunology | It is not widely known that there are several commonalities between respiratory and immunologic-driven diseases, including the impact they have on people’s everyday lives. Nearly 550 million people worldwide live with a respiratory disease ... |
| - | Inside the powerful political machines that COVID-19 vaccine makers Pfizer, Moderna, and AstraZeneca have built in DC | A man walks in front of Pfizer headquarters on November 18, 2020 in New York City. The company has developed a COVID-19 vaccine. It's also built an army of lobbyists and spent millions of dollars to influence policy in Washington. Photo by ... |
| - | Endo Pharmaceuticals ends development of drug for growth hormone condition | Endo Pharmaceuticals (NASDAQ:ENDP) has ended its developments of an octreotide implant to treat a disorder in which the body produces too much growth hormone following a review of its research and development priorities, according to a fili... |
| - | Pitches unplugged: Startup developing iPad app to determine real reasons people don’t take their meds (video) | A medication adherence tool, an innovative lighting solution embedded in a cane and a device to measure brain activity for concussions were among the products pitched at a recent early stage venture event. Five companies made presentations,... |
| - | Reframing the lung cancer narrative to increase survival rates | This year in 2021, America will celebrate the 50th anniversary of the National Cancer Act, which established the National Cancer Institute and started the national “war on cancer.” While we’ve come a long way in raising awareness and increa... |
| - | Skepticism greets AstraZeneca in second round of changes announced this week | In AstraZeneca’s (NYSE: AZN) statement outlining additional changes the drug maker will make to its global business to achieve scientific leadership this week, it underscored the magnitude with a few words. “Focus” was mentioned 11 times — ... |
| - | AstraZeneca CEO faces familiar question on how to grow | Amidst calls by shareholders for a management shakeup, AstraZeneca (NYSE: AZN) CEO David Brennen sought to reassert his position in an interview with Bloomberg at the Pharmaceutical Research and Manufacturers of America’s annual meeting in ... |
| - | 5 healthcare social media tips that break the mold for pharma, med tech | Healthcare social media is becoming a necessity for pharmaceutical and medical device companies. With so much word of mouth recommendations being fueled by Facebook, Twitter and YouTube, to name a few, many industries that have a consumer m... |
| - | Biotech forum offers stage for new and mature entrepreneurs | The Innovation Forum at the Biotech 2011 conference in Philadelphia this week sought to put scientists and early stage startups from universities and incubators in the region in front of investors and alongside other, more mature startups t... |
| - | Endo Pharmaceuticals gets green light for generic version of Plendil | Endo Pharmaceuticals (NASDAQ: ENDP) has received approval from the Food and Drug Administration for its drug Felodipine extended-release tablets, a generic version of AstraZeneca‘s (NYSE: AZN) drug, Plendil.
The cardiovascular drug tallied ... |
| - | AstraZeneca shakes up R&D division with 1,600 staff cuts and shift to biotech hot spots (video) | AstraZeneca (NYSE:AZN) is revamping its research and development divisions to improve drug development by cutting 1,600 from its global operations and focusing R&D staff in three sites including Gaithersburg, Maryland. It plans to ditch... |
| - | FDA rejects diabetes drug from Bristol-Myers Squibb, AstraZeneca | Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca’s (NYSE:AZN) jointly developed treatment for type 2 diabetes has been turned down by U.S. regulators until lingering questions over the diabetes drug’s benefits and risks are addressed.
The U.... |
| - | Europe stocks close slightly lower after strong first half; mining stocks up 2% | This is CNBC’s live blog covering European markets. |
| - | Covid-19 has exposed existing disparities among underserved cancer patients, but community difference makers are fighting back | Underrepresented minority patient groups have historically faced diminished access to health care.
And while recent strides have addressed some inequities, the Covid-19 pandemic has widened these gaps, and risks undoing thirty years of prog... |
| - | From the lab to the patient: Priti’s story | By Priti Patel, MD, Vice President, Clinical Development, Hematology, AstraZeneca
Approximately every three minutes, a new patient is diagnosed with one of more than 130 different types of blood cancer.1,2 As a clinical drug developer, my r... |
| - | Survey of patient organizations finds cancer science communications too complex | The scientific understanding of the causes and mechanisms of cancers has advanced in recent years enabling scientists to develop new diagnostic methods and treatments that provide greater tumor precision and patient personalization. However... |
| - | FDA’s new statin label warning about diabetes risk may have little effect | In evaluating the new warning U.S. regulators are issuing on statin prescription labels, many physicians are likely to take the view that high cholesterol poses a greater risk to their patients than potential side effects like diabetes, mem... |
| - | CNBC Daily Open: Tesla roars in a quiet market | This report is from today’s CNBC Daily Open, our new, international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here. |
